Ardelyx Stock Earnings Reports

Ardelyx reported strong Q1 2026 commercial momentum with total product revenue of $93.4M (38% YoY growth). IBSRELA drove the quarter, generating $70.1M in revenue, up 58% YoY, with continued quarter-over-quarter demand growth despite seasonal dynamics and severe winter storms. XPHOZAH showed underlying paid-prescription growth (~19% YoY on a non‑Medicare basis) with total dispenses up 32% YoY. Management reiterated full-year 2026 revenue guidance: IBSRELA $410–$430M (50–57% YoY growth) and XPHOZAH $110–$120M, and reiterated a long-term XPHOZAH target of $750M and an IBSRELA target of at least $1B in 2029. Key near-term clinical development: the ACCEL Phase III trial testing IBSRELA in CIC (enrollment on track for completion by year-end, topline data expected H2 2027). Investing in pediatric studies (potential 6‑month patent extension) and a next‑generation NHE3 inhibitor (531) is ongoing. OpEx guidance is approximately $520M for 2026, reflecting increased R&D (ACCEL) and SG&A investments to support commercialization; Q1 net loss narrowed slightly to $37.6M. Cash position: $238.1M and a recently refinanced loan with SLR that extended maturities, lowered cost of capital, and leaves $100M available. Management emphasized disciplined capital allocation prioritizing IBSRELA growth, pipeline investment, and maintaining financial strength, with a path toward cash-flow positivity if revenue and expense execution continue as planned.